RRSS #4 - Blood Product Use Among Persons with Myelodysplastic Syndrome - Seattle

RRRSS

• 批准号: 7698421
• 金额: $ 17.88万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7698421
• 关键词: RRSS; #4; Blood; Product; Use

The myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant stem cell disorders characterized by dysplastic and ineffective blood cell production (i.e., apoptotic death) and a variable risk of transformation to acute leukemia. Patients with MDS often require blood products, yet the patterns of blood product use in persons with these conditions are unknown. In recent years, new treatments for MDS (e.g., thalidomide, lenalidomide) have become available that reduce the need for transfusions. On the other hand, management of MDS has become more aggressive over time, most notably through the use of growth factors (erythropoietin, G-CSF) and bone marrow transplant for advanced stage disease. In many cases, the impact of specific treatments¿including aggressive supportive care¿on patient survival remains unknown. Furthermore, the literature contains few large population-based observational studies of MDS patients. Our primary goals for this proposal are first to determine the feasibility of linking Western Washington SEER records with Puget Sound Blood Center records, and second, if successful, to determine patterns of blood product use following diagnosis for persons ages 21 and older diagnosed with MDS.

骨髓增生异常综合征（MDS）包括一组异质性的恶性干细胞疾病，其特征是发育不良和血细胞产生无效（即凋亡性死亡），并有转变为急性白血病的可变风险。MDS患者通常需要血液制品，但这些患者使用血液制品的模式尚不清楚。近年来，MDS的新治疗方法（如沙利度胺、来那度胺）已经出现，减少了输血需求。另一方面，随着时间的推移，MDS的治疗变得越来越积极，最明显的是通过使用生长因子（促红细胞生成素，G-CSF）和骨髓移植治疗晚期疾病。在许多情况下，具体治疗（包括积极的支持性护理）对患者生存的影响仍然未知。此外，文献中很少有大型基于人群的MDS患者观察性研究。我们的主要目标是首先确定将西华盛顿SEER记录与普吉特海湾血液中心记录联系起来的可行性，其次，如果成功的话，确定21岁及以上MDS患者诊断后血液制品的使用模式。